ATE407684T1 - Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels - Google Patents

Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels

Info

Publication number
ATE407684T1
ATE407684T1 AT02757918T AT02757918T ATE407684T1 AT E407684 T1 ATE407684 T1 AT E407684T1 AT 02757918 T AT02757918 T AT 02757918T AT 02757918 T AT02757918 T AT 02757918T AT E407684 T1 ATE407684 T1 AT E407684T1
Authority
AT
Austria
Prior art keywords
antibody
polyplex
therapeutic
antibody fragment
diagnostic agent
Prior art date
Application number
AT02757918T
Other languages
English (en)
Inventor
Esther Chang
Kathleen Pirollo
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE407684T1 publication Critical patent/ATE407684T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02757918T 2001-04-02 2002-04-02 Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels ATE407684T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28013401P 2001-04-02 2001-04-02

Publications (1)

Publication Number Publication Date
ATE407684T1 true ATE407684T1 (de) 2008-09-15

Family

ID=23071820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757918T ATE407684T1 (de) 2001-04-02 2002-04-02 Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels

Country Status (7)

Country Link
EP (1) EP1408996B1 (de)
AT (1) ATE407684T1 (de)
AU (1) AU2002307035A1 (de)
CA (1) CA2442533C (de)
DE (1) DE60228842D1 (de)
ES (1) ES2312608T3 (de)
WO (1) WO2002078608A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617514B2 (en) * 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
EP2001515A2 (de) * 2006-03-30 2008-12-17 The Regents of the University of California Ige-ausgerichteter dna-impfstoff
WO2007130462A2 (en) * 2006-05-04 2007-11-15 Alza Corporation Treating micrometastases using immunoliposomes comprising a chemotherapeutic agent, a targeting ligand and a hydrophilic polymer
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CN113384712A (zh) * 2021-06-11 2021-09-14 潍坊医学院 一种基于同时杀伤肿瘤细胞和CAFs的共载脂质体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642980B2 (en) * 1990-03-21 1993-11-04 Quest International B.V. Ultilization of enzymes
US5705655A (en) * 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
CA2194221C (en) * 1994-06-22 2001-01-02 Megabios Corporation Cationic amphiphiles
US5786214A (en) * 1994-12-15 1998-07-28 Spinal Cord Society pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system
US5977322A (en) * 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
ES2392246T3 (es) * 1996-11-12 2012-12-07 The Regents Of The University Of California Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo
WO1999059643A2 (en) * 1998-05-20 1999-11-25 Sdg, Inc. Liposomal delivery complex
JP4799736B2 (ja) * 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム

Also Published As

Publication number Publication date
EP1408996A4 (de) 2006-03-22
EP1408996B1 (de) 2008-09-10
WO2002078608A8 (en) 2004-06-03
DE60228842D1 (de) 2008-10-23
WO2002078608A2 (en) 2002-10-10
EP1408996A2 (de) 2004-04-21
CA2442533A1 (en) 2002-10-10
AU2002307035A1 (en) 2002-10-15
WO2002078608A3 (en) 2004-02-26
ES2312608T3 (es) 2009-03-01
CA2442533C (en) 2014-02-04

Similar Documents

Publication Publication Date Title
ATE261337T1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikro- und nanopartikeln mittels eines mikromischers
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
ATE555133T1 (de) Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
DE50004742D1 (de) Verfahren zur herstellung von polyetherpolyolen
ATE449153T1 (de) Verfahren zur herstellung eines waschmittels
ATE288502T1 (de) Gezieltes antikörper-verfahren
ATE442796T1 (de) Verfahren zur herstellung eines geräts mit einer gelschicht
ATE432063T1 (de) Verfahren zur herstellung von physiologisch aktiven substanzen enthaltenden dispersionen unter anwendung von hochdruck und hochscherkraft
ATE388167T1 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
DE69920945D1 (de) Verfahren zur herstellung von arzneistoffpartikeln
ATE407684T1 (de) Vereinfachtes und verbessertes verfahren zur herstellung eines antikörper- oder antikörperfragment-targeted immunoliposoms oder polyplex für die systemische verabreichung eines therapeutischen oder diagnostischen mittels
DE50007641D1 (de) Verfahren zur herstellung von polyetheralkoholen
DE59800058D1 (de) Karosseriehohlträger, sowie Verfahren zur dessen Herstellung mittels Innenhochdruck
DE602006000666D1 (de) Vorrichtung und Verfahren zur Herstellung von wellenförmigen Bändern
DE602004003037D1 (de) Verfahren und zwischenprodukte für die herstellung von emtricitabin
ATE322891T1 (de) Arzneistoffabgabesystem für wasser schwerlösliche arzneimittel
ATE402211T1 (de) Verfahren zur herstellung von farblosen, lagerstabilen biuretgruppenhaltigen polyisocyanaten
DE60308066D1 (de) Verfahren zur herstellung von hyperpolarisiertem 129xe
DE69912827T2 (de) "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
ATE440605T1 (de) Verfahren zur herstellung von camptothecin- derivaten
ATE320272T1 (de) Verwendung von kontrastmitteln zur herstellung eines diagnostischen mittels für die darm- lumenbildgebung
ATE416155T1 (de) Verfahren zur herstellung von bis-ä(3- dimethylamino)propylüamin (bisdmapa)
WO2007006581A3 (en) Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
EP4509190A4 (de) Geliermittel, verfahren zur herstellung des geliermittels und kosmetische zubereitung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties